Fulgent Genetics, Inc. FLGT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$25.27M-6.9% | -$23.65M-246% | -$6.83M+64.6% | -$19.26M-61.8% | -$11.9M-92.2% | ||
| $6M-1.8% | $6.11M+1.2% | $6.04M-0.3% | $6.05M+2.3% | $5.92M-4.4% | ||
| $9.89M+6.6% | $9.28M-4.5% | $9.72M-3.2% | $10.04M-4.8% | $10.55M+1.4% | ||
| -$1.12M-977% | -$104K+88.0% | -$864K-665% | -$113K+15.0% | -$133K+63.5% | ||
| $9K— | —— | $1K— | —— | $2K+102% | ||
| $1.19M-35.9% | $1.85M+64.4% | $1.13M-56.5% | $2.59M+24.9% | $2.08M— | ||
| -$16.43M-207% | $15.38M— | —— | $8.26M+82.5% | $4.52M-66.0% | ||
| -$408K-144% | $924K+1,006% | -$102K-126% | $386K+159% | -$658K— | ||
| -$2.12M-117% | $12.33M+1,189% | -$1.13M-122% | $5.2M+170% | -$7.49M— | ||
| -$2.79M-53.1% | -$1.82M-233% | $1.37M— | —— | -$804K-3.7% | ||
| -$1K— | —— | -$1K+91.7% | -$12K+42.9% | -$21K-200% | ||
| -$627K-147% | $1.33M— | —— | —— | $582K+180% | ||
| -$1.39M+98.1% | -$71.88M-299,404% | -$24K+99.9% | -$34.79M-2,076% | $1.76M-94.0% | ||
| $352K-37.9% | $567K+16.9% | $485K+34.0% | $362K+3.4% | $350K-26.6% | ||
| -$381K+14.6% | -$446K+5.1% | -$470K-32.4% | -$355K-0.3% | -$354K+26.7% | ||
| $7.1M+109% | -$78.14M— | —— | -$30.17M-581% | -$4.43M-118% | ||
| $5.2M+4.5% | $4.98M-17.7% | $6.05M-11.4% | $6.83M+44.7% | $4.72M+24.9% | ||
| $55.57M— | —— | —— | —— | $0— | ||
| $8K— | —— | $3K— | —— | $2K— | ||
| $10.94M-1.9% | $11.15M-41.6% | $19.08M-64.3% | $53.4M+92.6% | $27.73M+201% | ||
| $40.08M— | —— | —— | $2.21M-74.6% | $8.68M— | ||
| $476K— | —— | —— | $1K-99.8% | $470K— | ||
| $9K— | —— | —— | —— | $0-100% | ||
| $88K0.0% | $88K0.0% | $88K+1.1% | $87K-36.0% | $136K0.0% | ||
| $4.2M+840% | $447K+25.2% | $357K+3.5% | $345K-81.7% | $1.89M+680% | ||
| -$44.83M-8,296% | -$534K-20.0% | -$445K+83.1% | -$2.64M+76.4% | -$11.17M-3,317% | ||
| $3K-96.0% | $75K+400% | $15K+275% | $4K-63.6% | $11K+108% | ||
| -$26.79M+60.3% | -$67.45M-327% | $29.76M+44.5% | $20.6M+69.7% | $12.14M+519% | ||
| $44K+1,000% | $4K0.0% | $4K— | —— | $61K+22.0% | ||
| -$551K— | —— | $133K-99.6% | $32.75M+60,546% | $54K-94.3% | ||
| —— | $2.48M0.0% | $2.48M0.0% | $2.48M0.0% | $2.48M-1.5% | ||
| $9K— | —— | $1K— | —— | $2K+102% | ||
| -$2.12M-117% | $12.33M+1,189% | -$1.13M-122% | $5.2M+170% | -$7.49M— | ||
| $2.47M— | —— | $939K+1,048% | -$99K-219% | $83K-87.8% | ||
| -$381K+14.6% | -$446K+5.1% | -$470K-32.4% | -$355K-0.3% | -$354K+26.7% | ||
| -$2.79M-53.1% | -$1.82M-233% | $1.37M— | —— | -$804K-3.7% | ||
| $890K-5.5% | $942K-14.1% | $1.1M-22.0% | $1.41M-15.2% | $1.66M+7.3% | ||
| $352K-37.9% | $567K+16.9% | $485K+34.0% | $362K+3.4% | $350K-26.6% | ||
| -$1K— | —— | -$1K+91.7% | -$12K+42.9% | -$21K-200% | ||
| $1.19M-35.9% | $1.85M+64.4% | $1.13M-56.5% | $2.59M+24.9% | $2.08M— | ||
| -$199K+60.1% | -$499K-206% | -$163K-19.0% | -$137K0.0% | -$137K-108% | ||
| $8K— | —— | $3K— | —— | $2K— | ||
| $88K0.0% | $88K0.0% | $88K+1.1% | $87K-36.0% | $136K0.0% | ||
| $476K— | —— | —— | $1K-99.8% | $470K— | ||
| -$627K-147% | $1.33M— | —— | —— | $582K+180% | ||
| -$381K+14.6% | -$446K+5.1% | -$470K-32.4% | -$355K-0.3% | -$354K+26.7% | ||
| $141K— | —— | —— | —— | —— | ||
| $2.61M— | —— | —— | —— | $2.32M— | ||
| $210K-61.2% | $541K— | —— | —— | —— | ||
| -$551K— | —— | —— | —— | -$1.63M— | ||
| $1.9M+102% | -$83.12M— | $0+100% | -$37M-304% | -$9.15M— | ||
| $1.9M+102% | -$83.12M— | $0+100% | -$37M-304% | -$9.15M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Fulgent Genetics, Inc. generate?
- Fulgent Genetics, Inc. (FLGT) generated -$105.6M in operating cash flow over the trailing twelve months.
- What is Fulgent Genetics, Inc.'s free cash flow?
- After $23.1M of capital expenditures, Fulgent Genetics, Inc.'s free cash flow was -$118.2M over the trailing twelve months, down 138.2% year over year.
- Where does Fulgent Genetics, Inc.'s cash flow data come from?
- Every line is extracted from Fulgent Genetics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
